Gammagard
Gammagard is an immunoglobulin-based drug manufactured by Baxter International.[1] It is a brand of intravenous immunoglobulin.[2]
Early experimental results from a small clinical trial in humans have shown hints that it may protect against the progression of Alzheimer's Disease.[2][3]
In 2013 it failed a phase III clinical trial for Alzheimer's Disease.[4]
References
- ^ "Baxter's Gammagard shows potential in stabilizing Alzheimer's". The Pharma Letter. 18 July 2012. Retrieved 2012-07-19.
- ^ a b Andrew Pollack (July 17, 2012). "Small Trial Hints Drug Can Slow Alzheimer's". New York Times. Retrieved 2012-07-19.
- ^ "Experimental Alzheimer's drug Gammagard may stall memory decline, small study suggests". CBS News. 2012-07-17. Retrieved 2012-07-19.
- ^ Another Alzheimer's Drug Fails Phase III Trial
External links
 | This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |